<!DOCTYPE html>
<html lang="en">
<head>

<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">

<title>Human Kratom Studies | FDA Clinical Trial and Pharmacokinetic Data</title>

<meta name="description" content="Structured review of FDA-registered human kratom studies, including clinical trial NCT06072170 and controlled pharmacokinetic evaluations of mitragynine and 7-hydroxymitragynine.">

<meta name="keywords" content="kratom human study, NCT06072170, mitragynine clinical trial, 7-hydroxymitragynine metabolism, kratom drug liking, FDA kratom study">

<meta name="author" content="Kratom Regulatory Review">
<meta name="theme-color" content="#0c2d48">

<link rel="canonical" href="https://kratomregulatoryreview.org/human-studies.html">

<!-- Open Graph -->
<meta property="og:title" content="Human Kratom Studies | FDA Clinical Trial Data">
<meta property="og:description" content="Regulatory review of controlled human kratom studies including pharmacokinetics, 7-OH formation, and drug-liking findings.">
<meta property="og:type" content="website">
<meta property="og:url" content="https://kratomregulatoryreview.org/human-studies.html">

<!-- Google Analytics -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-MQKC65VZVY"></script>
<script async src="https://www.googletagmanager.com/gtag/js?id=G-P31PD1SSTD"></script>
<script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config','G-MQKC65VZVY');
gtag('config','G-P31PD1SSTD');
</script>

<link rel="stylesheet" href="css/style.css">

<style>
.page-header { padding: 40px 0 25px 0; }
.page-intro { max-width: 900px; margin-bottom: 14px; line-height: 1.7; }
.section { padding: 40px 0; }
.alt-bg { background:#f9fafb; }
.card { border:1px solid #e2e8f0; border-radius:12px; padding:20px; background:#fff; margin-bottom:22px; }
.card h3 { margin-top:0; }
.note { font-size:14px; color:#4b5563; line-height:1.6; }
.footer { background:#0c2d48; color:#fff; padding:30px 0; text-align:center; margin-top:40px; }
</style>

</head>
<body>

<div class="gov-banner">
üá∫üá∏ Informational public health resource. Educational reference for legislative and regulatory review.
</div>

<header class="site-header">
  <div class="container header-inner">
    <div class="site-title">Kratom Regulatory Review</div>
  </div>
</header>

<nav class="main-nav">
  <div class="container nav-inner">
    <a href="index.html">Overview</a>
    <a href="mortality.html">Mortality</a>
    <a href="adverse.html">Adverse Events</a>
    <a href="poison.html">Poison Control</a>
    <a href="KratomCaseReports.html">Case Reports</a>
    <a href="human-studies.html" class="active">Human Studies</a>
  </div>
</nav>

<section class="page-header">
  <div class="container">
    <h1>Human Kratom Studies</h1>

    <p class="page-intro">
      This page summarizes controlled human studies evaluating kratom (Mitragyna speciosa)
      and its primary alkaloids, mitragynine and 7-hydroxymitragynine (7-OH).
    </p>

    <p class="page-intro">
      Included are one FDA-registered clinical research result and peer-reviewed pharmacokinetic
      investigations examining safety, metabolism, subjective effects, and dose response
      under controlled laboratory conditions.
    </p>

  </div>
</section>
  <section class="section alt-bg">
  <div class="container">

    <div class="card">
      <h3>FDA-Registered Human Laboratory Study (ClinicalTrials.gov: NCT06072170)</h3>

      <p>
        This Phase I clinical study evaluated the safety and subjective effects
        of single-dose oral kratom powder in healthy adult volunteers.
        The study was conducted under controlled laboratory conditions.
      </p>

      <h4>Study Design</h4>
      <ul>
        <li>Healthy adult participants</li>
        <li>Opioid-experienced (not opioid-na√Øve)</li>
        <li>Single-dose administration</li>
        <li>Five escalating dose levels (up to approximately 12 grams of kratom powder)</li>
        <li>Placebo-controlled, clinical research setting</li>
      </ul>

      <p class="note">
        Phase I studies are designed to evaluate short-term safety and pharmacologic effects.
        They are not intended to evaluate long-term use, dependence, or chronic exposure.
      </p>

      <hr>

      <h4>Formation of 7-Hydroxymitragynine (7-OH)</h4>

      <p>
        The kratom material used in the study contained minimal pre-formed
        7-hydroxymitragynine (7-OH).
      </p>

      <p>
        However, measurable 7-OH was detected in participants‚Äô blood after dosing.
        This indicates that 7-OH was produced inside the body through metabolic
        conversion of mitragynine.
      </p>

      <p>
        7-OH has stronger activity at the mu-opioid receptor than mitragynine.
        Blood concentrations of 7-OH increased with higher kratom doses.
      </p>

      <p class="note">
        The presence of 7-OH in circulation reflects internal metabolic formation
        rather than high levels in the plant material itself.
      </p>

      <hr>

      <h4>Subjective Effects (‚ÄúDrug Liking‚Äù and ‚ÄúFeeling High‚Äù)</h4>

      <p>
        Participants completed standardized rating scales measuring subjective
        drug effects, including ‚Äúdrug liking‚Äù and ‚Äúfeeling high.‚Äù
      </p>

      <p>
        At higher doses, statistically significant increases in these measures
        were observed compared to placebo.
      </p>

      <ul>
        <li>Effects were dose-dependent.</li>
        <li>Lower doses produced minimal subjective changes.</li>
        <li>Higher doses produced measurable increases in reported drug effect.</li>
      </ul>

      <p>
        Reports of intense euphoria were limited, but measurable abuse-liability
        signals were present at higher dose levels.
      </p>

      <hr>

      <h4>Adverse Effects Observed</h4>

      <p>
        The most commonly reported treatment-emergent adverse events included:
      </p>

      <ul>
        <li>Nausea</li>
        <li>Dizziness</li>
        <li>Somnolence (sleepiness)</li>
        <li>Anxiety</li>
        <li>Presyncope (near-fainting)</li>
      </ul>

      <p>
        Adverse effects increased in frequency at higher dose levels.
      </p>

      <p>
        No deaths were reported. No severe respiratory depression was observed
        in this single-dose setting.
      </p>

      <hr>

      <h4>Participant Withdrawals</h4>

      <p>
        Some participants were withdrawn from the study:
      </p>

      <ul>
        <li>Elevated liver enzymes (ALT/AST) at higher dose levels</li>
        <li>Gastrointestinal intolerance</li>
        <li>Vasovagal syncope during blood draw (fainting episode)</li>
      </ul>

      <p>
        Two participants at the highest dose level were withdrawn due to
        liver enzyme elevations.
      </p>

      <p class="note">
        No serious adverse events were reported in this study.
      </p>

      <hr>

      <h4>Study Conduct and Sponsorship</h4>

      <p>
        The study was funded by a commercial kratom manufacturer
        (Johnson Foods / NP Pharma).
      </p>

      <p>
        Clinical trial operations were conducted by a contract research organization
        (SGS Nutrasource, Canada).
      </p>

      <p>
        Several authors disclosed consulting relationships with the sponsor.
      </p>

      <p>
        <a href="https://clinicaltrials.gov/study/NCT06072170?tab=results" target="_blank">
          View Full Trial Results on ClinicalTrials.gov ‚Üí
        </a>
      </p>

    </div>

  </div>
</section>
  <section class="section">
  <div class="container">

    <div class="card">
      <h3>2024 Human Pharmacokinetic Study (Molecules)</h3>

      <p>
        This peer-reviewed study evaluated how mitragynine and
        7-hydroxymitragynine (7-OH) move through the body after both
        single and repeated daily doses of dried kratom leaf powder.
      </p>

      <h4>Study Purpose</h4>
      <p>
        The goal was to measure blood concentrations, metabolism,
        accumulation over time, and steady-state levels under controlled conditions.
      </p>

      <hr>

      <h4>7-Hydroxymitragynine (7-OH) Formation</h4>

      <p>
        The kratom powder used in this study contained extremely low
        amounts of 7-OH prior to administration.
      </p>

      <p>
        After dosing, measurable 7-OH was detected in participant blood samples.
        This confirms that 7-OH was primarily produced through liver metabolism
        of mitragynine rather than being present in high concentrations
        in the original plant material.
      </p>

      <p>
        Although 7-OH blood levels were lower than mitragynine levels,
        7-OH was consistently detectable across dose levels.
      </p>

      <p class="note">
        7-OH has greater mu-opioid receptor activity than mitragynine.
        The study demonstrates that even low-7-OH plant material
        results in systemic exposure to this metabolite.
      </p>

      <hr>

      <h4>Single-Dose Findings</h4>

      <ul>
        <li>Blood levels of mitragynine increased proportionally with dose.</li>
        <li>7-OH levels increased alongside mitragynine.</li>
        <li>No unexpected metabolic byproducts were identified.</li>
      </ul>

      <p>
        Higher doses resulted in higher peak concentrations (Cmax)
        and overall drug exposure (AUC).
      </p>

      <hr>

      <h4>Repeated Daily Dosing (15 Days)</h4>

      <p>
        Participants received repeated daily doses for approximately two weeks.
      </p>

      <ul>
        <li>Steady-state concentrations were reached in approximately 7‚Äì9 days.</li>
        <li>Low-to-moderate accumulation of mitragynine was observed.</li>
        <li>7-OH remained detectable throughout repeated dosing.</li>
      </ul>

      <p>
        The ratio of 7-OH to mitragynine was highest after single doses
        and decreased somewhat with repeated dosing, but did not disappear.
      </p>

      <hr>

      <h4>Adverse Events</h4>

      <p>
        Reported adverse effects were similar to those seen in the 2026 safety trial:
      </p>

      <ul>
        <li>Nausea</li>
        <li>Dizziness</li>
        <li>Somnolence</li>
        <li>Headache</li>
      </ul>

      <p>
        No severe respiratory depression was observed in the controlled study setting.
      </p>

      <hr>

      <h4>Regulatory-Relevant Context</h4>

      <p>
        This study confirms that:
      </p>

      <ul>
        <li>7-OH is produced systemically after kratom ingestion.</li>
        <li>7-OH exposure increases with higher doses.</li>
        <li>Repeated dosing results in sustained exposure over time.</li>
      </ul>

      <p>
        The study does not evaluate long-term chronic use,
        dependence development, or polydrug use scenarios.
      </p>

      <hr>

      <h4>Funding Disclosure</h4>

      <p>
        The study was funded by Johnson Foods.
        Authors disclosed consulting relationships with the sponsor.
      </p>

      <p>
        <a href="assets/Huestis PK 2024.pdf" target="_blank">
          View Full Pharmacokinetic Study (PDF) ‚Üí
        </a>
      </p>

    </div>

  </div>
</section>
  <section class="section alt-bg">
  <div class="container">

    <div class="card">
      <h3>Summary Across Controlled Human Studies</h3>

      <p>
        Controlled human studies of kratom remain limited in number, but the studies summarized here
        provide structured information on metabolism, short-term tolerability, and measurable subjective effects
        under supervised conditions.
      </p>

      <h4>Key Findings (Plain Language)</h4>
      <ul>
        <li>
          <strong>7-hydroxymitragynine (7-OH) is produced in the body.</strong>
          Even when the kratom product contains very little 7-OH, participants still develop measurable 7-OH in blood,
          indicating metabolic conversion from mitragynine.
        </li>
        <li>
          <strong>Higher doses increase exposure.</strong>
          Both mitragynine and 7-OH blood levels rise with dose, and repeated dosing results in sustained exposure.
        </li>
        <li>
          <strong>Drug-effect ratings increase at higher doses.</strong>
          In the FDA-registered single-dose study, higher doses were associated with statistically significant increases
          in subjective ratings such as ‚Äúdrug liking‚Äù and ‚Äúfeeling high.‚Äù
        </li>
        <li>
          <strong>Short-term side effects were common and dose-related.</strong>
          Nausea, dizziness, headache, sleepiness, and similar effects were reported more often at higher doses.
        </li>
        <li>
          <strong>Some participants were withdrawn.</strong>
          Withdrawals occurred for reasons including elevated liver enzymes at higher doses and gastrointestinal intolerance.
        </li>
      </ul>

      <hr>

      <h4>What These Studies Do Not Evaluate</h4>
      <ul>
        <li>Long-term, high-frequency chronic use over months or years</li>
        <li>Adolescents and pediatric exposures</li>
        <li>Population-level incidence (how common events are in the general public)</li>
        <li>Real-world retail variability, including concentrated extracts and polydrug use</li>
        <li>Development of dependence and withdrawal under long-term daily use</li>
      </ul>

      <p class="note">
        Controlled trials are designed to measure effects under specific conditions. Surveillance systems
        (mortality, poison control, adverse event reporting) capture broader real-world patterns and are presented
        elsewhere on this site.
      </p>
    </div>

    <div class="card">
      <h3>Primary References</h3>
      <ul>
        <li>
          FDA-registered study results (ClinicalTrials.gov): 
          <a href="https://clinicaltrials.gov/study/NCT06072170?tab=results" target="_blank">NCT06072170 ‚Üí</a>
        </li>
        <li>
          Therapeutic Drug Monitoring (2026) safety/tolerability trial (PDF):
          <a href="assets/Huestis%20study%202026.pdf" target="_blank">Open PDF ‚Üí</a>
        </li>
        <li>
          Molecules (2024) pharmacokinetics study (PDF):
          <a href="assets/Huestis%20PK%202024.pdf" target="_blank">Open PDF ‚Üí</a>
        </li>
      </ul>
    </div>

  </div>
</section>

<footer class="footer">
  <div class="container">
    <p>¬© 2026 Kratom Regulatory Review</p>
  </div>
</footer>

</body>
</html>
